PTC Therapeutics: Will the Long-Term Market Penetration with the Drug Sephience Succeed? Experts See 74% Price Potential!
Reading Time: 2 minutes
The biotechnology company PTC Therapeutics is benefiting from robust revenue growth driven by the drug Sephience. Wells Fargo confirms a buy recommendation with a price target of 112 USD, indicating significant upside potential. The management raises the annual forecast and assesses the current market penetration as on schedule. Specialization in Rare Diseases as the Basis of the Business Model PTC Therapeutics (PTCT) is a biopharmaceutical company focused on the discovery and marketing of drugs for rare diseases. Addressed growth trends...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
